BANB Share Price Performance
CHF 67.90
18.04 (36.18%)
72.8% undervalued intrinsic discount
CHF 249.99
Fair Value
Price CHF 67.90
Peptide_gcr CHF 249.99
AnalystConsensusTarget CHF 78.30
AnalystHighTarget CHF 110.00
Fair ValueCHF 249.99
Share Pricen/a
Bachem Holding AG Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
BANB Community Narratives
PE
Fair Value
·Fair Value CHF 249.99 72.8% undervalued intrinsic discount
Bachem Holding - The Purest Public Peptide Play?
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CHF 78.3 13.3% undervalued intrinsic discount
Building K Production Will Serve Peptide And Oligonucleotide Therapies
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value
·Fair Value CHF 110 38.3% undervalued intrinsic discount
Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Bachem Holding - The Purest Public Peptide Play?
We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.Read more
PE
CHF 249.99
72.8% undervalued intrinsic discount
Fair Value
Revenue
62.01% p.a.
Profit Margin
21.41%
Future PE
34.2x
Price in 2029
CHF 286.91
Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand
Key Takeaways Rapid facility ramp-ups and integrated process innovations could drive substantial, underestimated margin and efficiency gains, outpacing analyst expectations for growth and profitability. Leadership in advanced peptide and oligonucleotide manufacturing, coupled with regulatory and ESG strengths, uniquely positions Bachem to capture market share and secure recurring revenue.Read more
AN
CHF 110
38.3% undervalued intrinsic discount
Fair Value
Revenue
31.34% p.a.
Profit Margin
20.01%
Future PE
30.07x
Price in 2029
CHF 125.64
Building K Production Will Serve Peptide And Oligonucleotide Therapies
Key Takeaways Significant expansion in large-scale manufacturing and process automation positions Bachem for outsized growth and improved margins amid rising demand for peptide and oligonucleotide drugs. Strong long-term customer partnerships and leadership in advanced therapeutics offer recurring, less volatile revenue and structural advantage as biopharma outsourcing intensifies.Read more
AN
CHF 78.3
13.3% undervalued intrinsic discount
Fair Value
Revenue
24.76% p.a.
Profit Margin
18.87%
Future PE
26.47x
Price in 2029
CHF 89.37
Strict Global Regulation And Rising Costs Will Impede Peptide Capacity
Key Takeaways Intensifying regulations, pricing pressures, and rising competition threaten Bachem's revenue growth, profitability, and ability to maintain premium market positioning. Large capital investments amid uncertain demand risk underutilization, weaker returns, and cash flow constraints if sector innovation or market share trends shift unfavorably.Read more
AN
CHF 49.3
37.7% overvalued intrinsic discount
Fair Value
Revenue
21.52% p.a.
Profit Margin
18.11%
Future PE
18.95x
Price in 2029
CHF 56.27
Trending Discussion
Recently Updated Narratives
PE
Bachem Holding - The Purest Public Peptide Play?
Fair Value: CHF 249.99 72.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BANB: Future Upside Will Depend On Executing Profit Margin Assumptions
Fair Value: CHF 110 38.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential
Fair Value: CHF 78.3 13.3% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bachem Holding AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 30, 2026
- 1.99
- 28.74%
- 21.41%
- 3.9%
About BANB
- Founded
- 1971
- Employees
- 2363
- CEO
- WebsiteView website
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
